Cargando…

Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography (Diabetes Metab J 2023;47:104-17)

Detalles Bibliográficos
Autor principal:	Roh, Eun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Diabetes Association 2023
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040619/ https://www.ncbi.nlm.nih.gov/pubmed/36944453 http://dx.doi.org/10.4093/dmj.2023.0051

Ejemplares similares

Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography (Diabetes Metab J 2023;47:104-17)
por: Kim, Hwi Seung, et al.
Publicado: (2023)

Safety of COVID-19 Vaccines among Patients with Type 2 Diabetes Mellitus: Real-World Data Analysis (Diabetes Metab J 2023;47:356-65)
por: Kim, Hye Jun, et al.
Publicado: (2023)

Safety of COVID-19 Vaccines among Patients with Type 2 Diabetes Mellitus: Real-World Data Analysis (Diabetes Metab J 2023;47:356-65)
por: Ohn, Jung Hun
Publicado: (2023)

Association of Body Mass Index and Fracture Risk Varied by Affected Bones in Patients with Diabetes: A Nationwide Cohort Study (Diabetes Metab J 2023;47:242-54)
por: Park, So Young
Publicado: (2023)

Association of Body Mass Index and Fracture Risk Varied by Affected Bones in Patients with Diabetes: A Nationwide Cohort Study (Diabetes Metab J 2023;47:242-54)
por: Lee, Se-Won, et al.
Publicado: (2023)

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
por: Lin, Tzu-Yi, et al.
Publicado: (2023)

Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists (Diabetes Metab J 2023;47:394-404)
por: Ko, Jihee, et al.
Publicado: (2023)

Association of Myosteatosis with Nonalcoholic Fatty Liver Disease, Severity, and Liver Fibrosis Using Visual Muscular Quality Map in Computed Tomography
por: Kim, Hwi Seung, et al.
Publicado: (2023)

Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
por: Lee, Da Young
Publicado: (2023)

Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
por: Scherbak, Nikolai N., et al.
Publicado: (2023)

Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9)
por: Huh, Ji Hye
Publicado: (2022)

Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9)
por: Seo, Da Hea, et al.
Publicado: (2022)

Response: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
por: Chung, Goh Eun, et al.
Publicado: (2020)

Letter: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
por: Jung, Chan-Hee
Publicado: (2020)

Letter: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
por: Kwon, Hyuktae
Publicado: (2020)

Response: Sarcopenia Is Significantly Associated with Presence and Severity of Nonalcoholic Fatty Liver Disease (J Obes Metab Syndr 2019;28:129-38)
por: Chung, Goh Eun, et al.
Publicado: (2020)

Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707)
por: Kim, Mi-kyung
Publicado: (2021)

Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707)
por: Han, Eugene, et al.
Publicado: (2021)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Nonalcoholic fatty liver disease in spinal and bulbar muscular atrophy
por: Guber, Robert D., et al.
Publicado: (2017)

The role of recipient myosteatosis in graft and patient survival after deceased donor liver transplantation
por: Czigany, Zoltan, et al.
Publicado: (2021)

Re: Daniel D. Joyce, Matteo Soligo, Alessandro Morlacco, et al. Effect of Preoperative Multiparametric Magnetic Resonance Imaging on Oncologic and Functional Outcomes Following Radical Prostatectomy. Eur Urol Open Sci 2023;47:87–93
por: Tandogdu, Zafer, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease and Abdominal Fat Accumulation According to Vitamin D Status in Patients with Type 2 Diabetes (J Obes Metab Syndr 2018;27:53–60)
por: Hwang, Juchul, et al.
Publicado: (2018)

Nonalcoholic Fatty Liver Disease and Abdominal Fat Accumulation According to Vitamin D Status in Patients with Type 2 Diabetes (J Obes Metab Syndr 2018;27:53–60)
por: Kim, Bo-Yeon, et al.
Publicado: (2018)

Diagnostic Performance of the Fibrosis-4 Index and Nonalcoholic Fatty Liver Disease Fibrosis Score in Lean Adults With Nonalcoholic Fatty Liver Disease
por: Park, Huiyul, et al.
Publicado: (2023)

Radiological assessment of skeletal muscle index and myosteatosis and their impact postoperative outcomes after liver transplantation
por: Petric, Miha, et al.
Publicado: (2023)

The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease
por: Cichoż-Lach, Halina, et al.
Publicado: (2012)

Inhibition of HSD17B13 protects against liver fibrosis by inhibition of pyrimidine catabolism in nonalcoholic steatohepatitis
por: Luukkonen, Panu K., et al.
Publicado: (2023)

Various myosteatosis selection criteria and their value in the assessment of short- and long-term outcomes following liver transplantation
por: Meister, Franziska Alexandra, et al.
Publicado: (2021)

Association of Visceral Fat Obesity, Sarcopenia, and Myosteatosis with Non-Alcoholic Fatty Liver Disease without Obesity
por: Kim, Hong-Kyu, et al.
Publicado: (2023)

Progression of liver fibrosis is associated with non‐liver‐related mortality in patients with nonalcoholic fatty liver disease
por: Tada, Toshifumi, et al.
Publicado: (2017)

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease
por: Arai, Taeang, et al.
Publicado: (2021)

Liver Proliferation Is an Essential Driver of Fibrosis in Mouse Models of Nonalcoholic Fatty Liver Disease
por: Cast, Ashley, et al.
Publicado: (2019)

Liver fibrosis is associated with risk for colorectal adenoma in patients with nonalcoholic fatty liver disease
por: Kim, Min Cheol, et al.
Publicado: (2019)

Association between Smoking and Liver Fibrosis among Patients with Nonalcoholic Fatty Liver Disease
por: Ou, Hongjie, et al.
Publicado: (2019)

Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective
por: Soon, Gwyneth, et al.
Publicado: (2021)

Nonalcoholic Fatty Liver Disease, Liver Fibrosis and Cardiovascular Disease in the Adult US Population
por: Ciardullo, Stefano, et al.
Publicado: (2021)

Influence of liver stiffness heterogeneity on staging fibrosis in patients with nonalcoholic fatty liver disease
por: Kawamura, Nobuyoshi, et al.
Publicado: (2022)

Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future
por: Yu, Jung Hwan, et al.
Publicado: (2023)

Quantitative assessment of liver fibrosis reveals a nonlinear association with fibrosis stage in nonalcoholic fatty liver disease
por: Masugi, Yohei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_fjtfkpj7ib7ojiic0ni2nequi9